STOCK TITAN

Casi Pharmaceuticals Inc (CASI) Net Income by Year

CASI

Casi Pharmaceuticals Inc reported a net loss of $48.1M in fiscal year 2025. This represents a decrease of 22.4% from the prior fiscal year. The table below carries 6 fiscal years, from 2020 to 2025, and the quarters Casi Pharmaceuticals Inc has filed alongside them.

FY2025 annual
Net Income -$48.1M
YoY -22.4%
Source SEC Filings (10-K/10-Q) Latest period FY2025, ended Dec 31, 2025 Reported Currency USD

Annual figures, oldest first. Point at a bar to read its period.

CASI Net Income by Fiscal Year

Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.

MetricFY2510-KFY2410-KFY2310-KFY22FY21FY20
Net Income-$48.1M-22.4%-$39.3M-45.6%-$27.0M+34.3%-$41.0M-11.9%-$36.7M+24.1%-$48.3M

CASI Net Income by Quarter

Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.

MetricQ4'2510-KQ4'2410-KQ4'23Q4'22Q4'21
Net IncomeN/AN/AN/AN/AN/A

What net income means

Net income is what is left of revenue once every cost is counted, interest and tax included, so a company can grow its sales and still report a loss on this line.

More Casi Pharmaceuticals Inc financials

Frequently Asked Questions

What was Casi Pharmaceuticals Inc's net income in fiscal year 2025?

Casi Pharmaceuticals Inc reported a net loss of $48.1M in fiscal year 2025.

How fast is Casi Pharmaceuticals Inc's net income growing?

Casi Pharmaceuticals Inc (CASI) net income fell by 22.4% year over year, from -$39.3M to -$48.1M in fiscal year 2025.

How has Casi Pharmaceuticals Inc's net income changed over the years?

Across the 6 fiscal years this page covers, Casi Pharmaceuticals Inc (CASI) net income went from -$48.3M in fiscal year 2020 to -$48.1M in fiscal year 2025.

Net income is what is left of revenue once every cost is counted, interest and tax included, so a company can grow its sales and still report a loss on this line. This page lists what Casi Pharmaceuticals Inc (CASI) reported on that line in every period on record.